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EVIDENCE FOR IMPAIRED 
T CELL DNA METHYLATION 
IN SYSTEMIC LUPUS ERYTHEMATOSUS 
AND RHEUMATOID ARTHRITIS 
BRUCE RICHARDSON, LEE SCHEINBART. JOHN STRAHLER, LAURA GROSS, 
SAMIR HANASH, and MARCIA JOHNSON 
Procainamide and hydralazine inhibit T cell 
DNA methylation and induce autoreactivity in cloned 
CD4+ T cells. These drugs also induce an autoimmune 
syndrome, suggesting a possible relationship between 
DNA hypomethylation, T cell autoreactivity, and cer- 
tain autoimmune diseases. To test this relationship, 
DNA methylation was studied in T cells from patients 
with rheumatoid arthritis and patients with systemic 
lupus erythematosus, and was found to be impaired. 
These results support a relationship between DNA hypo- 
methylation and some forms of autoimmune disease. 
Cytosine methylation in regulatory sequences 
of some genes is associated with transcriptional inac- 
tivation, while hypomethylation of these sequences is 
associated with active transcription (1-4). DNA methyl- 
transferase inhibitors such as 5-azacytidine inhibit 
methylation of newly synthesized DNA and allow 
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expression of genes suppressed by mechanisms asso- 
ciated with DNA methylation (5). 
In earlier experiments, cloned, antigen-specific, 
interleukin-2 (IL-2Mependent CD4+ T cells were 
treated with Sazacytidine, and it was found that the 
cells transiently lost antigen restriction and responded 
to autologous class 11 major histocompatibility com- 
plex (MHC) determinants without antigen. The altered 
reactivity was not due to exogenous lymphokines, was 
inhibited by anti-CD3 antibodies, and may be due to 
altered gene expression (6). Cloned CD8+ T cells 
treated with 5-azacytidine re-expressed CD4, but did 
not become autoreactive (7). Procainamide and hydrala- 
zine were subsequently found to inhibit T cell DNA 
methylation and induce a similar autoreactivity (8). 
Some patients receiving procainamide or hy- 
dralazine develop an autoimmune syndrome charac- 
terized by arthritis, serositis, and antinuclear antibod- 
ies (9), which could be caused by autoreactive T cells. 
This putative association between drug-induced T cell 
autoreactivity and autoimmunity is suggested by sim- 
ilarities to the murine chronic graft-versus-host (GVH) 
disease model, in which CD4+ T cells responding to 
host class I1 MHC determinants produce a disease 
resembling systemic lupus erythematosus (SLE), but 
with features of other connective tissue diseases, such 
as rheumatoid arthritis (RA), in some strains (10,ll). 
Taken together, these results suggested a possible 
relationship between T cell DNA hypomethylation, T 
cell autoreactivity, and some forms of autoimmune 
disease. Therefore, we examined T cell DNA methyl- 
ation in patients with SLE and RA, diseases in which 
autoreactive T cells could be pathogenic (12,13). 
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PATIENTS AND METHODS 
Patients. Patients were recruited from the University 
of Michigan Hospitals and Clinics, the Ann Arbor Veterans 
Administration Hospital, and University of Michigan Affil- 
iated Hospitals. RA patients fulfilled 4 or more of the 
American Rheumatism Association ( A M )  criteria for RA 
(141, and SLE patients fulfilled 4 or more of the ARA criteria 
for SLE (15). The activity of SLE was assessed using the 
method of Barada et al (16), and RA activity was assessed 
according to the ARA criteria for clinical remission (17). To 
be included in the study, patients with osteoarthritis (OA) 
were required to have radiographic evidence of the disease, 
and crystal identification was required for patients with gout. 
The diagnosis of multiple sclerosis (MS) was based on 
clinical manifestations, as described (18). Healthy individu- 
als who answered advertisements for volunteers served as 
controls. Informed consent was obtained in all cases. 
Isolation of T cells and T cell subsets. Peripheral blood 
mononuclear cells were isolated from venous blood by 
density gradient centrifugation, and T cells were separated 
from non-T lymphocytes by rosetting with sheep erythro- 
cytes (19). T cells purified by this method are usually 293% 
CD2+. Where indicated, purified T cells were cultured in 
RPMI 1640 medium (Gibco, Grand Island, NY) supple- 
mented with 10% fetal calf serum (Hyclone. Logan, UT) and 
activated with 0.5-1 .O pg/ml of phytohemagglutinin (PHA) 
(Burroughs Wellcome, Greenville, NC). Activated T cells 
were maintained as proliferating lines by the regular addition 
of IL-2 (supernatant from the MLA-144 cell line) (20). 
Purified T cells were fractionated into CD4t  and CD8+ 
subsets using antLCD8 or anti-CD4 (Ortho Pharmaceuticals, 
Raritan, NJ) and complement (Pel-Freez, Brown Deer, WI), 
as described (21). 
Table 1. Methylation of T cell DNA in autoimmune disease pa- 
tients and in controls* 
Age. % deoxymethylcytosine 
Group (n) years content 
Control (26) 33.6 ? 2.6 3.81 f 0.09 
MS (7) 36.4 f 3.3 3.69 f 0.06 
Active SLE (8) 32.0 ? 2.9 3.15 f 0.19t 
Control (13) 43.5 ? 3.4 3.78 f 0.10 
Inactive SLE (12) 45.8 2 3.6 3.50 f 0.16 
Control (7) 52.4 f 3.7 3.63 f 0.08 
OA or gout (8) 57.1 t 4.0 3.54 f 0.12 
Chronic infection (6) 59.3 ? 3.6 3.61 f 0.18 
RA (22) 57.1 5 2.1 3.28 f 0.11s 
* DNA deoxymethylcytosine content was measured as described in 
Figure I .  Values are the mean 5 SEM. The first control group listed 
is age-matched controls for the MS and active SLE groups, the 
second control group is age-matched controls for the inactive SLE 
group, and the third control group is age-matched controls for the 
OA or gout group, the chronic infection group, and the RA group. 
MS = multiple sclerosis; SLE = systemic lupus erythematosus; OA 
= osteoarthritis; RA = rheumatoid arthritis. 
t P = 0.001 versus aged-matched control group (n = 26). by analysis 
of variance. 
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Figure 1. T cell DNA deoxymethylcytosine (d"C) content in pa- 
tients with autoimmune diseases and in controls. T cells were 
isolated from venous blood of subjects in the indicated study groups. 
DNA was isolated from the T cells, digested to nucleosides, and the 
dC and d"C contents were quantitated by high performance liquid 
chromatography. Percent d"C was calculated as (dmC)l(dC + d"C). 
Each open circle represents a different subject. In the majority of 
cases, each point represents the mean of 2 or  more determinations 
made from 1 DNA sample. The solid circles and bars represent the 
mean ? SEM of the points within each group. OA = osteoarthritis; 
MS = multiple sclerosis; RA = rheumatoid arthritis; SLE = 
systemic lupus erythematosus. 
Measurement of DNA deoxymethylcytosine (d"C) con- 
tent. T cell nuclei were lysed with sodium dodecyl sulfate, 
treated with RNase and proteinase K, and DNA was ex- 
tracted as previously described (8). The purified DNA was 
digested with DNase I, phosphodiesterase, and alkaline 
phosphatase (Sigma, St. Louis, MO), and the resulting 
nucleosides were separated by reverse-phase high perfor- 
mance liquid chromatography (HPLC) using a modification 
of a previously published technique (8). The modification 
included using 0.01M sodium acetate buffer, pH 3.5, moni- 
toring ultraviolet-absorbing material from 220 nm to 320 nm 
with a Waters (Milford, MA) 990 diode array detector, and 
performing peak integrations at 300 nm. These changes 
resulted in a slight (<6%) decrease in estimates of d"C 
content in a standardized T cell line. 
Deoxymethylcytosine content from 9 young (<30 
years) controls, 10 RA patients, and 6 SLE patients was 
measured using a previously described technique (8), and the 
data are included in Table I and Figure 1. It should be noted 
that inclusion of these data diminishes, rather than aug- 
ments, differences between the disease and control groups. 
In most cases, 2 or more determinations were made on DNA 
isolated from each subject. These values were averaged, and 
entered into the analysis as a single value for each subject. 
The standard deviation of these replicate determinations was 
-0.05%. 
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The effect of medications on T cell d"C content was 
determined by treating the transformed human T cell leu- 
kemia line Jurkat with drugs as described (8), and then 
determining DNA d"C content. The drugs (dexamethasone, 
aurothioglucose, chloroquine. D-penicillamine, and indo- 
methacin) used in these studies were obtained from Sigma. 
DNA methyltransferase activity. T cells were acti- 
vated with PHA and expanded with IL-2 as described above. 
Nuclei were isolated with Triton X-100 as described (8) and 
stored at -70°C until used. DNA methyltransferase was 
prepared using a modification of the method of Lu and 
Randerath (22). Nuclei were suspended in 5 volumes of 
methylase buffer (50 mM Tris HCI, 1 mM dithiothreitol, I 
mM EDTA, 10% glycerol. 0.1 mM phenylmethylsulfonyl 
fluoride, pH 7.8) containing 0.4M NaCl. The mixture was 
stirred at 4°C for 20-30 minutes, and centrifuged at l5,OOOg 
for 30 minutes. DEAE-cellulose (Sigma) was prepared as 
described by Roe et al (23). and was added to the superna- 
tant to make a 25% (volumeivolume) suspension. The sus- 
pension was incubated at 4°C for 30 minutes and centrifuged 
at 12,OOOg for 30 minutes at 4°C. The protein content of the 
supernatant was measured using a modification of the pro- 
cedure of Lowry et al (24). 
The supernatant was assayed for DNA methyltrans- 
ferase activity in round-bottom microtiter wells. The reac- 
tion mixture contained (in a final volume of 150 pl of 
methylase buffer) 25-75 pg of methyltransferase. 2 pg of 
KNase A (Sigma) preheated at 80°C for 10 minutes, 2.5 pg of 
Micrococcus lritrus DNA (Sigma), and 5.0 pM [CH,-3H]- 
labeled S-adenosylmethionine (SAM) (5-15 Ciimmole: New 
England Nuclear, Boston. MA). The mixture was incubated 
at 37°C for 1 hour. Pronase (50 pg; Calbiochem, San Diego, 
CA) was then added, and the sample was incubated at 37°C 
for an additional 30 minutes. The reaction mixture was 
adjusted to a concentration of 0.5M NaOH and incubated at 
60°C for 30 minutes. The DNA was precipitated with ethanol 
onto fiberglass strips using a PHD cell harvester (Cambridge 
Tech Inc.. Watertown, MA). Precipitated "-labeled DNA 
was measured with a 1209 Rackbeta liquid scintillation 
spectrometer (LKB, Turku, Finland). All determinations 
were performed in triplicate. Using this protocol. DNA 
methyltransferase activity from a reference Jurkat T cell line 
was 6.4 2 0.4 disintegrations per minuteipg of proteinihour 
(mean ? SEM of 3 independent experiments). 
SAM and S-adenosylhomocysteine determinations. 
Levels of SAM and S-adenosylhomocysteine were measured 
using a modification of the method described by Wagner et al 
(25). A 10% solution (100 pl) of trichloroacetic acid was 
added to -5 x lo7 washed, activated T cells, which were 
cultured as described above. A soluble fraction was recov- 
ered by centrifugation through a filter excluding compounds 
> 10,000 kd (Ultrafree-MC: Millipore. Bedford, MA) at 
12,000~ for 30 minutes at 4°C. Soluble compounds present in 
the filtrate were subjected to HPLC analysis on a 25-cm C18 
column (Ultrasphere: Becknian, San Ramon, CA). The 
compounds of interest were separated using the following 
gradient elution: mobile phase (eluent) A contained O.IM 
NaH,PO,, 0.5 mM EDTA, 8 mM heptane sulfonic acid 
(Sigma), and 1.1% (viv) acetonitrile, pH 3.10, adjusted with 
H,PO,; mobile phase (eluent) B contained 0.1M NaH,PO,, 
5.69 mM heptane sulfonic acid, and 50% (v/v) acetonitrile, 
pH 3.10. An exponential gradient (curve 4, Waters 680 
system controller) was used. The elution was initiated with 
90% eluent A and 10% eluent B and ended with a mixture of 
35% eluent A and 65% eluent B over a 30-minute time 
period. The column was equilibrated with 90% eluent A and 
10% eluent B for 15 minutes prior to each injection. The 
column effluent was monitored with a Waters 990 diode 
array detector. The spectra were recorded from 220 nm to 
320 nm at intervals of 1 second. Integrations were performed 
at 260 nm. SAM and S-adenosylhomocysteine levels were 
quantitated relative to purified standard (obtained from 
Sigma). Reference SAM preparations were further purified 
before use, by chromatography on sulfopropyl Sephadex 
(Pharmacia. Uppsala, Sweden), as described by Glazer and 
Peale (26). 
Flow cytometric analysis. Purified T cells were 
stained with RD1-anti-CD4 and fluorescein isothiocyanate 
(FITC)-conjugated anti-CD8, FITC-conjugated anti-CD2 
and RD 1-anti-HLA-DR, or FITC-conjugated anti-CD2 
and RDI-anti-IL-2 receptor (IL-2R) (Coulter, Hialeah, 
FL) and analyzed by 2-color flow cytometry, as described 
previously (7). 
Statistical analysis. Differences between groups were 
analyzed using analysis of variance, and differences between 
means were tested, where indicated, using Student's t-test, 
with correction for multiple comparisons. 
RESULTS 
Hypomethylation of DNA in T cells from patients 
with RA and active SLE. DNA was isolated from 
peripheral blood T cells of 26 healthy controls (age 
range 21-65 years) and from 7 patients with OA, 1 with 
gout, 5 with chronic osteomyelitis, 1 with chronic 
histoplasmosis, 7 with MS, 22 with RA, 8 with active 
SLE. and 12 with inactive SLE. The purified DNA 
was hydrolyzed to  nucleosides, and the percentage of 
methylated cytosine residues was determined by 
HPLC analysis. The  results are shown in Figure 1. The  
percent d"'C values overlapped between groups, but 
the healthy controls had the highest values, while RA 
patients and SLE patients with active disease had the 
lowest values ( P  < 0.001). The  study patients fell into 
3 age ranges. Since T cell d"C content normally 
decreases with age (27), the healthy controls were 
divided into groups that were age matched with those 
of the patients (Table 1). Patients with active SLE had 
significantly less T cell d"C than age-matched controls 
( P  = 0.001), while patients with inactive SLE did not, 
although a trend toward decreased values was noted. 
T cell DNA from patients with RA was also 
significantly hypomethylated relative to age-matched 
controls (P = 0.02). In contrast t o  the SLE groups, no 
difference in T cell d"C was noted between patients 
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Table 2. Non-T lymphocyte DNA methylation in autoimmune 




Control (1 1) 
Active SLE (6) 
OA or gout (7) 
RA (16) 
3.65 t 0.17 
3.52 f 0.25 
3.29 t 0.17 
3.23 2 0.15 
* DNA deoxymethylcytosine content was measured as described in 
Figure I .  Values are the mean SEM. See Table 1 for definitions. 
No significant differences between groups were observed, by ana- 
lysis of variance. 
with active and inactive RA (mean & SEM 3.27 ? 
0.16% versus 3.28 & 0.15%, respectively). Within the 
RA and SLE groups, 10 of 22 RA patients and 4 of 8 
SLE patients with active disease had d"C levels more 
than I SD outside the normal range. No clinical 
parameters were found to distinguish these patients. T 
cell d"C content in patients with OA, gout, chronic 
infection, and MS was not significantly different from 
that in age-matched controls. 
DNA methylation in SLE and RA non-T lympho- 
cytes. To test if DNA was hypomethylated in cells 
other than T cells, DNA d"C content was measured in 
non-T lymphocytes isolated from RA, SLE, and OA 
or gout patients and from controls (Table 2). In con- 
trast to the results obtained using T cell DNA, DNA 
d"C content was comparable in non-T lymphocytes 
from the RA and ONgout groups, and in patients with 
active SLE and age-matched controls. Although a 
trend toward DNA hypomethylation was suggested in 
the older groups, the difference was not statistically 
significant, due to interpatient variability. DNA d"C 
content was lower in non-T lymphocytes than in T 
lymphocytes in the OA/gout group, but this difference 
was also not statistically significant. 
Mechanisms of DNA hypomethylation. The T 
cell DNA hypomethylation observed in patients with 
Table 3. DNA deoxymethylcytosine content in T cells of healthy 
controls, classified according to the sex of the individual and T cell 
stimulation by phytohemagglutinin (PHA)* 
% deoxymethylcytosine 
Group (n) content 
All controls (26) 
Men (16) 
Women (10) 
PHA-stimulated cells (14) 
3.81 t 0.09 
3.84 2 0.14 
3.76 2 0.06 
3.85 f 0.21 
~ _ _ _ _ _  _____ ~ ~ 
* DNA content was measured as described in Figure I .  Values are 
the mean 2 SEM. 
Table 4. Effect of phytohemagglutinin (PHA) stimulation and T 
cell subsets on the DNA deoxymethylcytosine (d"C) content of T 
cells from healthy controls* 
d"C content 
Ratio 
T cells % (range) (mean -t- SEM) 
Contro1:cultured controlt 3.16-3.6 1 1.01 2 0.05 
CD4: CD8$ 3.224.15 0.99 ? 0.01 
* DNA d"C content was measured as described in Figure I .  
t DNA d"C content was measured in T cells from 6 healthy controls 
on day 0 and 2 weeks after T cell activation by phytohemagglutinin 
and culturing with interleukin-2 (cultured control). Values are the 
range of d"C levels in the 6 subjects and the mean f SEM of the 
control cell d"C: cultured cell d"C ratios in the 6 subjects. 
f T cells from 6 healthy controls were fractionated into CD4+ and 
CD8+ populations, and the DNA d"C content was determined for 
each population. Values are the range of dmC levels in the 6 subjects 
and the mean ? SEM of the CD4 dmC:CD8 d"C ratios in the 6 
subjects. 
RA and in patients with active SLE could be second- 
ary to T cell activation, differences in d"C content 
between T cell subsets, or differences in T cell DNA 
methylation between men and women. The effect of 
the sex of the individual and of T cell activation on T 
cell d"C content is presented in Table 3. DNA meth- 
ylation was essentially identical in T cells from healthy 
men and women. The effect of T cell activation on 
DNA methylation was examined by stimulating T cells 
from 14 healthy donors with PHA and measuring d"C 
content 3-4 days later. No change in DNA methylation 
was seen following PHA activation. 
The effect of chronic activation on T cell DNA 
methylation was examined by comparing d"C content 
in freshly isolated T cells and in PHA-activated T cells 
that had been maintained as proliferating lines for 2 
weeks with IL-2 (Table 4). The T cell d"C content in 
6 healthy controls ranged from 3.16% to 3.61%. After 
2 weeks in culture, T cell d"C was again measured, 
and the ratio of (d"C in freshly isolated cells):(d"C in 
cultured cells) was determined for each subject. The 
measured d"C values were essentially identical, indi- 
cating that DNA methylation is stable in proliferating 
T cells for at least 2 weeks. To study whether d"C 
varied between T cell subsets, T cells from 6 controls 
were separated into CD4+ and CD8+ subsets, and 
d"C content was assayed (Table 4). The range of 
values obtained was 3.22-4.15%, and for each subject, 
the d"C content in each subset was nearly identical. 
Lack of effect of drug therapy on T cell DNA 
methyfation. Medications could also be responsible for 
T cell DNA hypomethylation in patients with RA and 
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Table 5. Medications taken by the study subjects* 
Gold 
Group (n)  NSAID HCQ salts Pred AZA MTX CYC 
OA or gout (8) 7 0 0 0 0 0 0  
Chronic infection (6) 0 0 0 0 0 0 0 
MS (7) 0 0 0 0 0 0 0  
RA (22) 2 1 3 8 8 1 2 0  
Active SLE (8) 4 4 0 5 1 1 0  
Inactive SLE (12) 6 6 0 4 0 0 0  
* NSAID = nonsteroidal antiinflammatory drug; HCQ = hydroxy- 
chloroquine: Pred = prednisone; AZA = azathioprine; MTX = 
methotrexate; CYC = cyclophosphamide. See Table I for other 
definitions. 
active SLE. Table 5 summarizes the antirheumatic 
medications taken by these patients, and lists the 
number of patients in the other 4 disease groups who 
were taking similar medications. No other medications 
were being taken by significant numbers of patients in 
the RA and SLE groups. Adrenocorticosteroids and 
gold salts were the only agents used widely in RA and 
SLE patients and not in other disorders. The T cell 
d"C content in RA patients receiving gold salts was 
(mean * SEM) 3.43 ? 0.18%, compared with 3.19 2 
0.13% in RA patients not taking gold salts (I: > 0.05). 
The T cell d"C content in RA patients taking cortico- 
steroids was 3.00 2 0.14%, compared with 3.43 ? 
0.13% in RA patients not taking these drugs ( P  > 
0.05). No significant differences in T cell d"C content 
were found between patients who were taking cortico- 
steroids and those not taking these drugs, in either the 
inactive SLE group (3.61 ? 0.12% versus 3.45 5 
0.24%, respectively), or the active SLE group (3.21 2 
0.28% versus 3.05 2 0.28%, respectively). 
Since a trend toward DNA hypomethylation 
was found in the steroid-treated RA patients. the effect 
of corticosteroids on DNA methylation was examined 
further. The leukemic T cell line Jurkat was treated 
with IO-*M to 10p5M dexamethasone. and the DNA 
d"C content was determined with the procedures 
previously used to demonstrate inhibition by procain- 
amide (8). Seven to 9 determinations were made at 
each dexamethasone concentration. No  inhibition of 
DNA methylation was observed at any of the concen- 
trations tested. Similar studies using 10-4M to 10p6M 
aurothioglucose, 10-4M to lO-'M chloroquine, lOP4M 
to 10-7M D-penicillamine, and lOP5M to 10pxM indo- 
methacin confirmed that these medications did not 
inhibit DNA methylation in vitro. 
Table 6. DNA methyltransferase activity in T cell nuclear proteins 
from patients with rheumatoid arthritis (RA) and systemic lupus 
eryrhematosus (SLE)* 
DNA methyltransferase activity 
Group (n)  (dpm/pg/hour) 
Control ( 5 )  6.1 2 0.74 
RA ( 5 )  4.7 2 0.58 
Active SLE ( 5 )  2.1 t 0.36t 
* T cells were isolated from the indicated populations, activated 
with phytohemagglutinin, and expanded with interleukin-2. DNA 
methyltransferase was isolated and measured as described in Pa- 
tients and Methods. Values are the dpm of 'H incorporated into 
DNA per pg of protein per hour, mean t SEM of triplicate 
determinations from the indicated number of subjects. 
t P = 0.001 versus controls and versus RA patients, by analysis of 
variance. 
Effect of DNA methyltransferase activity and 
SAM and S-adenosylhornocysteine levels on T cell 
DNA methylation. It is possible that DNA hypomethyl- 
ation in RA or SLE T cells could be due to diminished 
DNA methyltransferase activity, decreased intracellular 
SAM pools, or increased S-adenosylhomocysteine pools 
(28). Since DNA methyltransferase is expressed only in 
proliferating lymphocytes (29) and SAM levels are max- 
imal in activated cells (301, T cells from patients with RA 
and active SLE and from normal controls were activated 
with PHA and expanded in media supplemented with 
1L-2. The nuclei were then isolated, DNA methyltrans- 
ferase was partially purified, and enzymatic activity was 
measured. The comparison of methyltransferase activity 
between these groups is shown in Table 6. Controls 
without autoimmune disease and RA patients had a p  
proximately equivalent amounts of methyltransferase 
activity. The slightly higher value in the control group is 
due to 1 healthy individual with reproducibly greater 
amounts of methyltransferase activity than the other 
subjects (8.8 dpm/pg/hour). It should be noted that the 
DNA d"'C content in these RA patients, determined 
simultaneously with methyltransferase activity, was 
(mean ? SEM) 3.20 2 0.24%. In contrast to controls and 
RA patients, T cell nuclear proteins from the patients 
with active SLE examined contained significantly less 
enzymatic activity ( P  = 0.001). 
SAM and S-adenosylhomocysteine levels were 
determined in activated T cells from the RA patients 
and controls, to test whether changes in these inter- 
mediate products could be responsible for DNA hypo- 
methylation in the RA group. No significant differences 
were found, suggesting that this possibility is unlikely. 
Coexpression of CD4 and CD8 in T cells from RA 
and SLE patients. Since CD8+ cells treated with DNA 
methylation inhibitors in vitro may coexpress CD4 and 
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CD8 (7), we tested whether hypomethylated T cells 
from RA and SLE patients coexpressed CD4 and CD8, 
using 2-color flow cytometry. T cells from these pa- 
tients were also tested for expression of HLA-DR and 
IL-2R because CD4+, CD8+ cells transiently appear 
during activation of CD4+ cells (31). Eight RA pa- 
tients with diminished DNA d"C content were exam- 
ined, and a small increase in cells coexpressing CD4 
and CD8 was observed compared with 70 normal 
controls (mean * SEM 2.73 * 0.70% versus 1.12 2 
0.27%; P < 0.025). In contrast, none of the 11 SLE 
patients tested (5 with active disease and 6 with 
inactive disease) demonstrated elevated numbers of 
CD4+, CD8+ cells. There was no increase in HLA- 
DR-bearing or IL-2R-bearing cells in the RA patients, 
suggesting that the CD4+, CD8+ cells were not due to 
T cell activation. 
DISCUSSION 
DNA methylation can affect gene expression, 
and changes in cellular DNA methylation have been 
implicated in differentiation (32) and carcinogenesis 
(33). This is the first study examining DNA methyl- 
ation in idiopathic autoimmune diseases. We report that 
T cell DNA from -50% of the patients with RA and 
active SLE contained reduced amounts of 5-methyl- 
cytosine. Comparisons were made with T cell DNA 
from normal subjects and patients with inactive SLE 
or other diseases, and no similar decrease was found. 
There was also no decrease of DNA methylation in the 
SLE non-T cell population. 
It is not certain why only half the patients with 
RA and active SLE had hypomethylated DNA. The 
variability in d"C content in patients with active SLE 
could reflect a transient abnormality in all SLE pa- 
tients, or may identify a disease subset characterized 
by DNA hypomethylation. Due to the large amount 
(100 ml) of blood required for accurate T cell d"C 
measurement, and the fact that patients with SLE 
were anemic (34), we were unable to perform serial 
d"C measurements in the same patients. However, 
many of the patients with inactive SLE had previously 
experienced disease flares similar to the active disease 
group, and their DNA could have been hypomethylat- 
ed at those times. 
In contrast to SLE, no correlation with disease 
activity was found in RA patients. However, disease 
activity in this group was determined by clinical crite- 
ria, and many of the patients were receiving cortico- 
steroids, gold salts, and/or nonsteroidal antiinflamma- 
tory drugs, which could prevent detection of some of 
the clinical manifestations of disease activity. There- 
fore, we cannot exclude a relationship between dis- 
ease activity in RA and DNA methylation. 
The decrease in DNA methylation could be 
confined to 1 T cell subset, rather than all T cells. In 
healthy donors with a wide range of total T cell 
methylcytosine content, CD4+ and CD8+ cells dem- 
onstrated similar d'"C values. However, accurate mea- 
surement of d"C content in the less prevalent CD8+ 
population required 500 ml of blood. Again, since the 
RA and SLE patients were anemic, it was impractical 
to obtain this volume of blood from these patients. 
We examined mechanisms predisposing to 
DNA hypomethylation. The T cell DNA hypomethyl- 
ation could not be accounted for by differences in age, 
sex, intracellular levels of methylation precursors, T 
cell activation, or type of medication. Chronic T cell 
activation could be a factor affecting T cell DNA 
methylation, and remains a possibility, especially in 
RA. Others have proposed that DNA methyltrans- 
ferase, the enzyme which replicates DNA methylation 
patterns, may occasionally fail to methylate a cytosine 
residue. and an accumulation of these errors in chron- 
ically proliferating cells could lead to DNA hypomethyl- 
ation (3). To control for this, we examined patients 
with MS and patients with active, chronic infections 
and found that they did not have hypomethylated T 
cell DNA. Furthermore, PHA-stimulated T cells and 
IL-2-dependent T cell lines cultured for 2 weeks 
showed no changes in d"C content. Taken together, 
these results provide evidence against chronic T cell 
stimulation as the primary cause of DNA hypomethy- 
lation. However, it remains possible that chronic T 
cell stimulation, as seen in RA, could slowly produce 
DNA hypomethylation over a period of years and not 
be found in these controls. 
When DNA methyltransferase activity was 
measured in controls, RA patients, and patients with 
active SLE, the SLE patients were found to have 
approximately bne-third to one-half as much enzy- 
matic activity as the other groups. Although the study 
group was small, the results were statistically signifi- 
cant, and suggest that impaired methyltransferase ac- 
tivity may contribute to DNA hypomethylation in 
some SLE patients. This conjecture is supported by 
our finding that procainamide inhibits T cell DNA 
methyltransferase in vitro (35). Since procainamide 
also induces a lupus-like syndrome (9), it is possible 
that diminished DNA methyltransferase activity is the 
common link between idiopathic and procainamide- 
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induced lupus. The reason for diminished enzymatic 
activity is unknown. Possible explanations include 
increased levels of methyltransferase inhibitors such 
as methinin (36), or altered amounts or specific activity 
of DNA methyltransferase in these cells. Studies eval- 
uating these mechanisms in larger numbers of patients 
will be informative, and are currently under way. 
Environmental factors have also been shown to 
affect DNA methylation. For example, procainamide, 
hydralazine (8), and ultraviolet light (37) are inhibitors 
of DNA methylation. These factors are particularly 
interesting because of their relationship with SLE, and 
other environmental factors may be identified in fur- 
ther studies. It is possible that some of the patients 
studied were exposed to an environmental DNA meth- 
ylation inhibitor, causing DNA hypomethylation that 
was then maintained by DNA methyltransferase. 
Finally, others have noted abnormal DNA me- 
tabolism in lymphocytes from SLE patients. In these 
studies, greater amounts of low molecular weight 
DNA fragments were found in PHA-stimulated lym- 
phocytes from SLE patients than from controls 
(38,39). It is possible that DNA hypomethylation may 
be related to this alteration in DNA metabolism. but 
the mechanism linking these 2 observations is unclear. 
In summary, multiple mechanisms may contrib- 
ute to DNA hypomethylation in these patients. The 
evidence obtained in these studies suggests that hy- 
pomethylation in SLE may be due to impaired meth- 
yltransferase activity in some patients. In RA patients, 
no clear cause was identified, and the hypomethylation 
most likely represents an accelerated loss of dmC 
secondary to aging or chronic T cell stimulation. 
The DNA hypomethylation observed in RA and 
SLE could be involved in the pathogenesis of these 
diseases by altering expression of certain crucial genes 
and thereby inducing T cell autoreactivity . The extent 
of hypomethylation required to alter expression of 
these putative genes is unknown. Cytosine methyl- 
ation appears to affect protein binding to DNA (40,41), 
and relatively few methylcytosine residues in regula- 
tory sequences can affect gene expression (42). As- 
suming that cytosine demethylation is random and that 
relatively few methylcytosines regulate expression of 
the putative gene(s) contributing to autoreactivity, the 
probability of demethylating the crucial residue(s) 
would follow a normal distribution, and progressive 
DNA demethylation would increase the likelihood of 
demethylating the crucial base(s). Also, genetic fac- 
tors clearly predispose certain individuals to RA and 
SLE (43). It is likely that if DNA hypomethylation 
contributes to the pathogenesis of RA or SLE, addi- 
tional genetic factors are also required. These obser- 
vations could explain the overlap in DNA methylcy- 
tosine levels between some of the controls and the 
patients with RA and active SLE. 
It is possible to estimate the number of genes 
potentially affected by changes in DNA methylation. 
In RA patients, the decrease in d"C content relative to 
young healthy controls is 0.53%, and the decrease in 
patients with active SLE is 0.66%. Methylcytosine 
occurs in CG basepairs, and in vertebrate DNA, there 
are approximately 20,824 CG basepairs/106 bases (44). 
Assuming 3 x lo9 basepairskell, a decrease of 0.53% 
corresponds to a decrease of 33 1,000 demethylated 
cytosine residues, and a decrease of 0.66% corre- 
sponds to a decrease of 412,000 residues. These num- 
bers are sufficient to affect the expression of a large 
number of genes, and are comparable in magnitude 
with the decrease induced by Sazacytidine, procain- 
amide, and hydralazine (8). 
The genes affected by DNA methylation are not 
well identified. Our group has reported that cloned 
CD8+ cells treated with 5-azacytidine can re-express 
CD4 (7), and in the present study, a small but statisti- 
cally significant number of T cells from RA patients, 
but not SLE patients, expressed both markers. CD4+, 
CD8+ cells have been previously described in RA 
(45). It is possible that this abnormal phenotype could 
be due to DNA hypomethylation. However, this phe- 
notype was expressed on a small percentage of T cells, 
while DNA hypomethylation appears to affect a ma- 
jority of the T cells. Furthermore, none of the patients 
with active SLE expressed this marker. Therefore, 
these results suggest that if DNA methylation directly 
affects CD4 expression in CD8 cells, either crucial 
sequences regulating CD4 expression are only rarely 
demethylated in these patients or cells expressing both 
markers are eliminated or sequestered away from 
venous blood. 
Alternatively, additional factors beyond DNA 
hypomethylation may be required to affect CD4 gene 
expression, since cloned, IL-2-dependent cell lines 
are exposed to conditions not found in vivo. More 
persuasive evidence for altered gene expression in RA 
and SLE patients will await identification of other T 
cell genes affected by DNA methylation inhibitors, 
some of which may be responsible for the T cell 
autoreactivity observed when T cells are treated with 
these inhibitors in vitro. 
Evidence for the presence of autoreactive T 
cells in RA and SLE remains hypothetical, based on 
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the chronic GVH model (10,Il). While autoreactive T 
cells in these diseases have been sought using the 
autologous mixed lymphocyte reaction, with largely 
negative results (46), autoreactive cells could be dis- 
tributed in places other than peripheral venous blood, 
such as lymphatic tissue, or could be refractory to 
restirnulation (47). Therefore, our results remain con- 
sistent with a model in which T cell DNA hypometh- 
ylation alters gene expression and generates autoreac- 
tive T cells, which then participate in the pathogenesis 
of RA and SLE. 
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